{
    "clinical_study": {
        "@rank": "46924", 
        "arm_group": [
            {
                "arm_group_label": "Obese subjects with normal uric acid", 
                "arm_group_type": "No Intervention", 
                "description": "Subjects with a body mass index = or > 30 kg/m2 with normal uric acid (= or < 5 mg/dL)"
            }, 
            {
                "arm_group_label": "Obese subjects with high uric acid", 
                "arm_group_type": "Experimental", 
                "description": "Subjects with a body mass index = or > 30 kg/m2 with high uric acid (>6 mg/dL)\nIntervention: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to learn more about what is the effect of uric acid on\n      oxidative stress and on the way the body metabolizes sugar in obese people. Understanding\n      this may lead to better diseases such as diabetes."
        }, 
        "brief_title": "Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Obesity", 
            "Metabolic Syndrome", 
            "Hyperuricemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Obesity", 
                "Metabolic Syndrome X", 
                "Hyperuricemia", 
                "Insulin Resistance"
            ]
        }, 
        "detailed_description": {
            "textblock": "It has been hypothesized that oxidative stress is involved in the pathogenesis of insulin\n      resistance associated with obesity. Circulating uric acid (UA) is the body's major\n      endogenous plasma antioxidant. Therefore, the investigators evaluated whether alterations in\n      serum UA concentration affect: 1) systemic and skeletal muscle oxidative stress, 2) total\n      antioxidant capacity, and 4) skeletal muscle insulin sensitivity during a\n      hyperinsulinemic-euglycemic clamp."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  obese (BMI 30-45 kg/m2);\n\n          -  serum UA concentration either \u22655 mg/dL or \u22644.0 mg/dL (297 \u00b5mol/L)],\n\n        Exclusion Criteria:\n\n          -  renal dysfunction (serum creatinine >1.5 mg/dL);\n\n          -  pregnancy or lactating;\n\n          -  take urate-lowering agents, thiazide diuretics, prednisone or medications containing\n             aspirin or other salicylates ;\n\n          -  history of xanthinuria, type 2 diabetes or other significant organ system\n             dysfunction;\n\n          -  have G6PD deficiency;\n\n          -  use hormone-replacement or oral-contraceptive therapy;\n\n          -  smoke tobacco;\n\n          -  anemic (Hb <10 g/dl)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "31", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01931527", 
            "org_study_id": "06-0509"
        }, 
        "intervention": {
            "arm_group_label": "Obese subjects with high uric acid", 
            "description": "one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min", 
            "intervention_name": "Rasburicase", 
            "intervention_type": "Drug", 
            "other_name": "Elitek"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Uric Acid", 
                "Rasburicase"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Obesity", 
            "Metabolic syndrome", 
            "Hyperuricemia"
        ], 
        "lastchanged_date": "December 9, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "St Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Washington University School of Medicine"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Plasma Uric Acid on Insulin Sensitivity, Endothelial Function and Inflammation", 
        "other_outcome": [
            {
                "description": "A hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotope glucose tracer infusion will be used to measure skeletal muscle insulin sensitivity in obese subjects with either high or normal uric acid at baseline", 
                "measure": "Determine differences between people with high or normal uric acid on insulin sensitivity", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "description": "Systemic (urinary isoprostanes) and skeletal muscle (carbonylated protein ratio) oxidative stress and total antioxidant capacity (plasma and saliva TRAP and FRAP) will be measured in obese subjects with either high or normal uric acid at baseline", 
                "measure": "Determine differences in people with high or normal uric acid in oxidative status", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }
        ], 
        "overall_official": {
            "affiliation": "Washington University School of Medicine", 
            "last_name": "Samuel Klein, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Uric acid will be reduced to 0 with a 30 minute infusion of a uricase (Elitek, Sanofi-Aventis). A hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotope glucose tracer infusion will be used to measure skeletal muscle insulin sensitivity in obese subjects with high uric acid before and after uric acid reduction.", 
            "measure": "Determine the effect of reducing uric acid on insulin sensitivity", 
            "safety_issue": "No", 
            "time_frame": "12 hours after reducing uric acid"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01931527"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Uric acid will be reduced to 0 with a 30 minute infusion of a uricase (Elitek, Sanofi-Aventis). Systemic (urinary isoprostanes) and skeletal muscle (carbonylated protein ratio) oxidative stress and total antioxidant capacity (plasma and saliva TRAP and FRAP) will be measured in obese subjects with high uric acid before and after uric acid reduction.", 
            "measure": "Determine the effect of reducing uric acid on oxidative status", 
            "safety_issue": "No", 
            "time_frame": "12 hours after reducing uric acid"
        }, 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2006", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}